Myovant Sciences Price to Free Cash Flow Ratio 2017-2021 | MYOV
Historical price to free cash flow ratio values for Myovant Sciences (MYOV) since 2017.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Myovant Sciences Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2021-12-03 |
14.66 |
|
3.25 |
| 2021-09-30 |
22.44 |
$4.50 |
4.98 |
| 2021-06-30 |
22.77 |
$2.87 |
7.94 |
| 2021-03-31 |
20.58 |
$4.10 |
5.02 |
| 2020-12-31 |
27.62 |
$4.83 |
5.72 |
| 2020-09-30 |
14.05 |
$-2.30 |
0.00 |
| 2020-06-30 |
20.62 |
$-2.58 |
0.00 |
| 2020-03-31 |
7.55 |
$-2.59 |
0.00 |
| 2019-12-31 |
15.52 |
$-3.11 |
0.00 |
| 2019-09-30 |
5.20 |
$-3.26 |
0.00 |
| 2019-06-30 |
9.05 |
$-3.53 |
0.00 |
| 2019-03-31 |
23.87 |
$-3.37 |
0.00 |
| 2018-12-31 |
16.41 |
$-3.13 |
0.00 |
| 2018-09-30 |
26.55 |
$-2.75 |
0.00 |
| 2018-06-30 |
22.87 |
$-2.24 |
0.00 |
| 2018-03-31 |
21.27 |
$-1.98 |
0.00 |
| 2017-12-31 |
12.64 |
$-1.63 |
0.00 |
| 2017-09-30 |
15.47 |
$-1.26 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.368B |
$0.059B |
|
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
|
